Literature DB >> 11380253

Phospholipases stimulate secretion in RBL mast cells.

J S Cohen1, H A Brown.   

Abstract

Roles for glycerophospholipids in exocytosis have been proposed, but remain controversial. Phospholipases are stimulated following the activation of the high-affinity receptor for immunoglobulin E (IgE) in mast cells. To study the biochemical sequelae that lead to degranulation, broken cell systems were employed. We demonstrate that the addition of three distinct types of exogenous phospholipases (i.e., bcPLC, scPLD, and tfPLA(2)), all of which hydrolyze phosphatidylcholine (PC), trigger degranulation in permeabilized RBL-2H3 cells, a mucosal mast cell line. Production of bioactive lipids by these phospholipases promotes release of granule contents through the plasma membrane and acts downstream of PKC, PIP(2), and Rho subfamily GTPases in regulated secretion. These exogenous phospholipase-induced degranulation pathways circumvent specific factors activated following stimulation of the IgE receptor as well as in ATP- and GTP-dependent intracellular pathways. Taken together, these results suggest that regulated secretion may be achieved in vitro in the absence of cytosolic factors via phospholipase activation and that products of PC hydrolysis can promote exocytosis in mast cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380253     DOI: 10.1021/bi0103011

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  A role for phospholipase D1 in neurotransmitter release.

Authors:  Y Humeau; N Vitale; S Chasserot-Golaz; J L Dupont; G Du; M A Frohman; M F Bader; B Poulain
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Regulation of M2-type pyruvate kinase mediated by the high-affinity IgE receptors is required for mast cell degranulation.

Authors:  H Ryu; J K L Walker; S Kim; N Koo; L S Barak; T Noguchi; B Y Kang; K-M Kim
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 3.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

4.  Electrospray ionization mass spectrometry analysis of changes in phospholipids in RBL-2H3 mastocytoma cells during degranulation.

Authors:  P T Ivanova; B A Cerda; D M Horn; J S Cohen; F W McLafferty; H A Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Histamine release and surface CD200R1 staining as sensitive methods for assessing murine mast cell activation.

Authors:  David Larson; Edward Mitre
Journal:  J Immunol Methods       Date:  2012-02-28       Impact factor: 2.303

6.  ADP ribosylation factor 6 binding to phosphatidylinositol 4,5-bisphosphate-containing vesicles creates defects in the bilayer structure: an electron spin resonance study.

Authors:  M Ge; J S Cohen; H A Brown; J H Freed
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

7.  The cation channel mucolipin-1 is a bifunctional protein that facilitates membrane remodeling via its serine lipase domain.

Authors:  Janice M LaPlante; John L Falardeau; Edward M Brown; Susan A Slaugenhaupt; Peter M Vassilev
Journal:  Exp Cell Res       Date:  2011-01-20       Impact factor: 3.905

8.  Ordered and disordered phases coexist in plasma membrane vesicles of RBL-2H3 mast cells. An ESR study.

Authors:  Mingtao Ge; Arun Gidwani; H Alex Brown; David Holowka; Barbara Baird; Jack H Freed
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

9.  Rolling blackout is required for synaptic vesicle exocytosis.

Authors:  Fu-De Huang; Elvin Woodruff; Ralf Mohrmann; Kendal Broadie
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

Review 10.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.